Are nanotechnological approaches the future of treating inflammatory diseases?

anti-inflammatory drugs chronic inflammation immunosuppressive treatments mononuclear phagocytic system nanoparticles phagocytes tolerance

Journal

Nanomedicine (London, England)
ISSN: 1748-6963
Titre abrégé: Nanomedicine (Lond)
Pays: England
ID NLM: 101278111

Informations de publication

Date de publication:
09 2019
Historique:
pubmed: 16 8 2019
medline: 28 7 2020
entrez: 16 8 2019
Statut: ppublish

Résumé

The current treatments for chronic inflammatory diseases cause severe side effects due to nonspecific drug accumulation. Nanotechnology opens the way to new therapeutic strategies that exploit the ability of immune cells, and especially of phagocytes, to internalize nanoparticles. The cellular uptake of nanoparticles requires specific interactions and is affected by the chemical and physical properties of the carriers. Therefore, optimizing these properties is crucial for designing nanodrugs for immunotherapy. In perspective, we discuss the nanoparticle-based approaches that have been proposed to induce tolerance in autoimmune disorders and lessen the symptoms of inflammatory diseases.

Identifiants

pubmed: 31414616
doi: 10.2217/nnm-2019-0159
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2379-2390

Auteurs

Maria Antonietta Rizzuto (MA)

Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.

Lucia Salvioni (L)

Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.

Rany Rotem (R)

Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.

Miriam Colombo (M)

Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.

Ivan Zanoni (I)

Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.
Harvard Medical School and Division of Gastroenterology, Boston Children's Hospital, Boston, MA, USA.

Francesca Granucci (F)

Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.

Davide Prosperi (D)

Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.
Nanomedicine Laboratory, Surgery Department, ICS Maugeri, via S. Maugeri 10, 27100 Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH